R Pili
Overview
Explore the profile of R Pili including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deng X, Shao G, Zhang H, Li C, Zhang D, Cheng L, et al.
Oncogene
. 2016 Aug;
36(9):1223-1231.
PMID: 27546619
Protein arginine methyltransferase 5 (PRMT5) is an emerging epigenetic enzyme that mainly represses transcription of target genes via symmetric dimethylation of arginine residues on histones H4R3, H3R8 and H2AR3. Accumulating...
2.
Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, et al.
Oncogene
. 2015 Jun;
35(12):1541-53.
PMID: 26119935
Current standard of care for muscle-invasive urothelial cell carcinoma (UCC) is surgery along with perioperative platinum-based chemotherapy. UCC is sensitive to cisplatin-based regimens, but acquired resistance eventually occurs, and a...
3.
Armstrong A, Haggman M, Stadler W, Gingrich J, Assikis V, Polikoff J, et al.
Clin Cancer Res
. 2013 Nov;
19(24):6891-901.
PMID: 24255071
Purpose: Tasquinimod (Active Biotech) is an oral immunomodulatory, anti-angiogenic, and anti-metastatic agent that delayed metastatic disease progression in a randomized placebo-controlled phase II trial in men with metastatic castration-resistant prostate...
4.
Buck M, Raaijmakers L, Ramakrishnan S, Wang D, Valiyaparambil S, Liu S, et al.
Oncogene
. 2013 Nov;
33(41):4961-5.
PMID: 24186201
Recent studies have demonstrated that in clear cell renal cell carcinoma (ccRCC) several chromatin remodeling enzymes are genetically inactivated. Although, growing evidence in cancer models has demonstrated the importance of...
5.
Raymond E, Dalgleish A, Damber J, Smith M, Pili R
Cancer Chemother Pharmacol
. 2013 Oct;
73(1):1-8.
PMID: 24162378
Tasquinimod is a small molecule with pleiotropic effects on the tumour microenvironment. Tasquinimod inhibits the growth and metastasis of tumour cells in vitro and in vivo. It targets the tumour...
6.
Tolcher A, Chi K, Shore N, Pili R, Molina A, Acharya M, et al.
Cancer Chemother Pharmacol
. 2012 Jul;
70(2):305-13.
PMID: 22752297
Purpose: Abiraterone is the active metabolite of the pro-drug abiraterone acetate (AA) and a selective inhibitor of CYP17, a key enzyme in testosterone synthesis, and improves overall survival in postdocetaxel...
7.
Morris M, Eisenberger M, Pili R, Denmeade S, Rathkopf D, Slovin S, et al.
Ann Oncol
. 2012 May;
23(10):2714-2719.
PMID: 22553195
Background: This first-in-human phase I/IIA study was designed to evaluate the safety and pharmacokinetics (PKs) of AGS-PSCA a fully human monoclonal antibody directed to prostate stem cell antigen (PSCA) in...
8.
Carpiniello B, Pinna F, Pili R, Velluzzi F, Loviselli A
Int J Psychiatry Med
. 2012 Apr;
42(4):369-75.
PMID: 22530399
Objective: The authors sought to evaluate lifetime prevalence of mental disorders in patients affected by metabolic syndrome compared with patients affected by central obesity alone. Methods: One hundred eighty-six (63.5%)...
9.
Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, et al.
Br J Cancer
. 2011 Dec;
106(1):77-84.
PMID: 22134508
Background: Preclinical studies suggest that histone deacetylase (HDAC) inhibitors may restore tumour sensitivity to retinoids. The objective of this study was to determine the safety, tolerability, and the pharmacokinetic (PK)/pharmacodynamic...
10.
Pili R, Kruszewski M, Hager B, Lantz J, Carducci M
Cancer Res
. 2001 Mar;
61(4):1477-85.
PMID: 11245454
Differentiation-inducing agents, such as retinoids and short-chain fatty acids, have an inhibitory effect on tumor cell proliferation and tumor growth in preclinical studies. Clinical trials involving these compounds as single...